Business
Pulnovo Medical Announces Strategic Investment from Medtronic in oversubscribed $100 Million Financing Round
Pulnovo Medical, a pioneer in breakthrough therapies for treating Pulmonary Hypertension and Heart Failure, today announced the successful completion of an oversubscribed $100 million strategic financing round with a leading investment by Medtronic, one of the world's largest medical technology companies, alongside continued support from existing investors such as EQT, Qiming Venture Partners, Gaorong Ventures, OrbiMed, and Lilly Asia Ventures. Pulnovo also welcomes new investors, including HSG
About this update from Medtronic Plc.
[{"type":"text","content":"NEW YORK, April 19, 2026 /PRNewswire/ -- Pulnovo Medical, a pioneer in breakthrough therapies for treating Pulmonary Hypertension and Heart Failure, today announced the successful completion of an oversubscribed $100 million strategic financing round with a leading investment by Medtronic, one of the world's largest medical technology companies, alongside continued support from existing investors such as EQT, Qiming Venture Partners, Gaorong Ventures, OrbiMed, and Lilly Asia Ventures. Pulnovo also welcomes new investors, including HSG (formerly Sequoia China), and other prominent global investors. This financing represents a significant milestone in Pulnovo's global growth trajectory and reflects strong validation from leading strategic and institutional investors of the company's technology, clinical progress, and long-term vision.","length":861,"tagName":"p"},{"type":"text","content":"Separately, Medtronic and Pulnovo have entered into a commercial agreement that contemplates potential future commercialization opportunities. The agreement is designed to leverage the commercial synergy between Pulnovo and Medtronic and Medtronic's unique and extensive global commercialization capabilities.","length":313,"tagName":"p"},{"type":"text","content":"Pulnovo's proprietary Pulmonary Artery Denervation (PADN) System targets a key underlying mechanism of cardiopulmonary disease and has demonstrated meaningful clinical benefits, including improvements in functional capacity and patient outcomes. To date, the company has performed approximately 1,500 PADN procedures globally and has secured regulatory approvals in seven countries, supporting its expanding international footprint. Pulnovo is advancing commercialization across the European Union, Middle East, and China.","length":531,"tagName":"p"},{"type":"text","content":"In the United States, Pulnovo has received FDA Breakthrough Device designation and has initiated two fully approved Investigational Device Exemption (IDE) trials, both led by Dr. Gregg Stone, Senior Faculty and Professor at Mount Sinai.","length":236,"tagName":"p"},{"type":"text","content":""Through the integration of industry expertise and long-term capital, Pulnovo is building a scalable growth model anchored in proprietary innovation, global clinical development, and strategic ecosyst...